Citrus Bioflavonoids

Compound Class	Citrus bioflavonoids — predominantly flavanone glycosides, plus flavone glycosides and polymethoxyflavones
Representative Members	Hesperidin, naringin, diosmin, neohesperidin, eriocitrin; diosmetin and hesperetin as aglycones
Botanical Sources	Citrus species — particularly C. sinensis (orange) and C. aurantium (bitter orange)
Plant Part(s)	Peel and pith (albedo) — concentrated in the fruit by-product stream, not the juice
Typical Standardisation	Total bioflavonoids by HPLC; 40% common. Diosmin available separately at 90–95%
Primary Applications	Venoactive/chronic venous disease formulation, haemorrhoid support, cardiometabolic and lipid support
Claim Strength (Overview)	Moderate — the venoactive indication is well established in European clinical practice; hesperidin has meta-analysis-supported cardiometabolic effects
Buy from Herbuno	Citrus Bioflavonoid 40% Powder → Diosmin 95% Powder (Citrus-Derived) | High-Purity Flavone Glycoside | Citrus aurantium →

Name origin: "Bioflavonoid" is a commercial and historical term rather than a strict chemical class name, dating to the mid-20th century when the citrus flavonoid fraction was briefly and incorrectly designated "vitamin P" for its apparent effect on capillary permeability — a vitamin classification later withdrawn when no deficiency state could be established. The individual members carry taxonomic names: hesperidin from Hesperides (the mythological garden of golden apples), naringin from the Sanskrit narangi for orange. Traditional use: Citrus peel — the bioflavonoid-bearing part — has a substantial traditional-medicine record quite distinct from the fruit as food, appearing in Traditional Chinese Medicine as chen pi (aged tangerine peel) for digestive complaints and phlegm, and in European practice as a bitter tonic. The modern venoactive application, by contrast, is not traditional at all: it emerged from 20th-century French pharmaceutical development and is now embedded in European clinical guidelines for chronic venous disease. Research trajectory: The defining commercial development in this class was the micronized purified flavonoid fraction (MPFF) — a specific preparation of 90% micronized diosmin with 10% other citrus flavonoids — developed and clinically validated in Europe, where it has been used for decades as a drug or non-prescription treatment for chronic venous insufficiency and haemorrhoidal disease. Poor native oral bioavailability drove the micronization approach and remains the central technical constraint on the class. Commercial source: Citrus peel and pith extract standardized to total bioflavonoid content is the commercial format; diosmin is commercially produced by chemical conversion from hesperidin extracted from bitter orange.

---

Evidence for Citrus Bioflavonoids Applications

Hesperidin, the dominant citrus bioflavonoid by mass, has genuine meta-analytic support for cardiometabolic effects. An updated meta-analysis of randomized controlled trials pooling 12 trials with 589 participants found evident effects of hesperidin on LDL cholesterol (weighted mean difference −0.22 mmol/L), total cholesterol (−0.20 mmol/L), fasting blood glucose, insulin sensitivity, the adhesion molecules ICAM-1 and VCAM-1, and C-reactive protein (Adv Nutr 2024). The reductions in vascular adhesion molecules are mechanistically notable, as they point to a genuine endothelial effect rather than merely a lipid one — consistent with the class’s venoactive positioning. Claim strength: Moderate.

The venoactive application rests on a specific, defined preparation rather than on citrus bioflavonoids generically. The micronized purified flavonoid fraction — consisting of micronized diosmin at 90% together with hesperidin, diosmetin, linarin, and isorhoifolin making up the remaining 10% — has shown clinical efficacy in both chronic venous disease and haemorrhoidal disease, and the constituent flavonoids diosmin, diosmetin, linarin, and isorhoifolin are all synthesized from hesperidin extracted from bitter orange (Nutrients 2021). Formulators should understand that MPFF is a defined pharmaceutical-grade preparation, and a generic 40% citrus bioflavonoid extract is not equivalent to it. Claim strength: Moderate (for MPFF specifically).

Bioavailability is the central technical constraint on this class, and it has directly shaped commercial practice. Diosmin’s poor oral absorption drove the adoption of micronization — reducing particle size to increase dissolution and uptake — and although plasma levels improve after micronized administration, concentrations remain low and highly variable across published studies. Hesperidin faces a comparable limitation, with oral bioavailability reported below 25%. This is why particle size and delivery format are not incidental specifications for this class but determinative ones. Claim strength: Moderate.

Diosmin and hesperidin are chemically linked in a way that has direct sourcing consequences: commercial diosmin is not primarily isolated from plants but is manufactured by chemical conversion (dehydrogenation) of hesperidin extracted from bitter orange. This means diosmin is best understood as a semi-synthetic derivative of a natural precursor, a provenance fact that matters for formulators making "wholly natural" or "plant-derived" claims and one that should be confirmed with the supplier rather than assumed. Claim strength: High (production fact).

A significant safety and formulation caveat specific to this class concerns naringin, a major bioflavonoid of grapefruit and a constituent of some citrus fractions: naringin and related furanocoumarins in grapefruit are responsible for the well-known grapefruit–drug interaction, mediated by inhibition of intestinal CYP3A4, which can raise plasma concentrations of numerous prescription medications to clinically significant levels. Formulators should confirm the bioflavonoid profile of their material and be alert to this where grapefruit-derived fractions are involved. Claim strength: High (established interaction).

---

Dosage & Formulator Specification

Herbuno carries Citrus Bioflavonoid 40% powder, alongside isolated diosmin at 95%, 90%, and 10% grades, and a range of whole citrus extracts including orange peel, lemon, and lime. Formulators targeting the venoactive indication should note that the clinical evidence attaches to defined micronized diosmin-dominant preparations rather than to generic bioflavonoid extracts, and should specify accordingly.

Clinical dosing for the venoactive indication has centred on MPFF at 1,000 mg/day given in two divided doses in the established European regimen, with lower-dose micronized diosmin at 450 mg once daily also investigated. Hesperidin cardiometabolic trials in the meta-analysis above have used a range of doses across 12 trials. Particle size should be specified alongside dose for diosmin-containing formulations, as micronization materially affects absorption and an unmicronized product at the same nominal dose is not equivalent.

Analytical verification should specify total bioflavonoid content by HPLC with the individual profile reported — hesperidin, naringin, diosmin, and neohesperidin at minimum — since these differ substantially in activity and in interaction risk. For diosmin specifically, particle size distribution should be documented given micronization’s established effect on bioavailability, and the production route (semi-synthetic conversion from hesperidin) should be confirmed where natural-origin claims are being made.

Citrus bioflavonoids have a favourable safety record, with mild gastrointestinal effects and headache being the most commonly reported adverse events in the venoactive clinical literature. The principal caution is the CYP3A4 interaction associated with grapefruit-derived flavonoids and furanocoumarins, which can meaningfully elevate plasma levels of a wide range of prescription drugs; formulators should confirm whether their material carries grapefruit-derived fractions and label accordingly. Standard caution regarding use in pregnancy is appropriate given limited data.

---

Frequently Asked Questions — Citrus Bioflavonoids

What is MPFF and is it the same as a citrus bioflavonoid extract?
MPFF is the micronized purified flavonoid fraction — a defined preparation of 90% micronized diosmin plus 10% other citrus flavonoids (hesperidin, diosmetin, linarin, isorhoifolin), used clinically in Europe for chronic venous disease and haemorrhoids. A generic 40% citrus bioflavonoid extract is not equivalent to it, and the clinical evidence attaches to MPFF specifically.

Is diosmin a natural or semi-synthetic compound?
Effectively semi-synthetic. Commercial diosmin is not primarily isolated from plants but manufactured by chemical dehydrogenation of hesperidin extracted from bitter orange. This matters for anyone making "wholly natural" or "plant-derived" claims and should be confirmed with the supplier rather than assumed.

Do citrus bioflavonoids interact with medications?
Some do, significantly. Naringin and related furanocoumarins in grapefruit inhibit intestinal CYP3A4 and are responsible for the well-known grapefruit–drug interaction, which can raise plasma levels of many prescription medications to clinically meaningful levels. Formulators should confirm the bioflavonoid profile of their material and be alert to grapefruit-derived fractions.

Why does micronization matter for diosmin?
Because diosmin is poorly absorbed orally. Reducing particle size increases dissolution and uptake, which is why micronization became standard. Plasma levels improve after micronized administration though they remain low and variable. An unmicronized product at the same nominal dose is not therapeutically equivalent, making particle size a determinative specification rather than an incidental one.

Related compounds: Hesperidin, Naringin, Diosmin, Flavonoids

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery